Get the Stockscreener App
46.28
1.05%
0.48
Protagonist Therapeutics Inc stock is traded at $46.28, with a volume of 517.39K.
It is up +1.05% in the last 24 hours and down -12.70% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$45.80
Open:
$45.83
24h Volume:
517.39K
Relative Volume:
0.50
Market Cap:
$2.76B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
17.66
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
+13.18%
1M Performance:
-12.70%
6M Performance:
-1.57%
1Y Performance:
+80.99%
1-Day Range:
$45.80
$46.87
1-Week Range:
$41.10
$48.32
52-Week Range:
$24.22
$60.60
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
46.28 | 2.76B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
When the Price of (PTGX) Talks, People Listen - news.stocktradersdaily.com
Protagonist Therapeutics Reports Granting of Inducement Award | PTGX Stock News - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Protagonist Awards 20,000 Stock Options to Key New Hire at $46.95 - Stock Titan
The 4.2% return this week takes Protagonist Therapeutics' (NASDAQ:PTGX) shareholders five-year gains to 558% - simplywall.st
Protagonist Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:PTGX - Benzinga
Polycythemia Vera Market to Show Remarkable Growth Trends from - openPR.com
BTIG maintains Buy on Protagonist Therapeutics stock, $82 target By Investing.com - Investing.com Canada
Johnson & Johnson, Protagonist Tout Positive Results For Psoriasis Oral Pill Study - Benzinga
Protagonist Therapeutics (PTGX) Unveils Promising Data for Psori - GuruFocus
Revolutionary Once-Daily Pill Achieves Complete Skin Clearance in 75% of Teen Psoriasis Patients - Stock Titan
Winners and wishers: 9 potential Bay Area drug approvals coming this yearSan Francisco Business Times - The Business Journals
(PTGX) Investment Analysis - news.stocktradersdaily.com
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High? - Yahoo Finance
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025 - Bluefield Daily Telegraph
Why Protagonist Therapeutics, Inc. (PTGX) Went Up on Monday - MSN
Insider Sell: William Waddill Sells 4,000 Shares of Protagonist Therapeutics Inc (PTGX) - GuruFocus
Protagonist Therapeutics Takeda To Lead Regulatory Strategy For Rusfertide In Polycythemia Vera NDA - MarketScreener
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm - Business Wire
Protagonist Therapeutics (PTGX) Upgraded to Buy: Here's Why - MSN
Protagonist Therapeutics director Waddill sells $217,000 in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics director Waddill sells $217,000 in stock - Investing.com
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025? - MSN
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Fast Company Ranks Protagonist Among Elite Biotech Innovators: 2 FDA Filings Coming - StockTitan
D-Wave Quantum And IonQ Are Among Top Mid-Cap Stock Gainers Last Week (Mar 10-Mar 14): Are The Others In Your Portfolio? - Benzinga
Is Protagonist Therapeutics, Inc. (PTGX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock By Investing.com - Investing.com Canada
Protagonist Therapeutics CFO Ali Asif sells $1.46 million in stock - Investing.com India
Protagonist Therapeutics’ chief medical officer sells $1.7 million in stock - Investing.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $76.00 - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Victory Capital Management Inc. - Defense World
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by Bank of New York Mellon Corp - Defense World
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa
Protagonist Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Learn to Evaluate (PTGX) using the Charts - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $72.00 at BMO Capital Markets - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Hits New 1-Year High on Analyst Upgrade - Defense World
Protagonist Therapeutics: Much More Than Rusfertide In Place To Carry It (NASDAQ:PTGX) - Seeking Alpha
Wedbush Adjusts Protagonist Therapeutics Price Target to $70 From $58, Maintains Outperform Rating - Marketscreener.com
Protagonist Therapeutics Soars as Icotrokinra Drives Breakthroug - GuruFocus.com
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):